Stem definition | Drug id | CAS RN |
---|---|---|
4554 | 397864-44-7 |
Dose | Unit | Route |
---|---|---|
0.20 | mg | N |
0.11 | mg | N |
0.60 | mg | Inhal.aerosol |
0.60 | mg | Inhal.powder |
1.50 | mg | Inhal.solution |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 4.95 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 13.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 10.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 27, 2007 | FDA | GLAXOSMITHKLINE | |
April 22, 2009 | PMDA | GlaxoSmithKline K.K. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 675.23 | 19.55 | 232 | 14003 | 18676 | 56259156 |
Asthma | 636.98 | 19.55 | 380 | 13855 | 112390 | 56165442 |
Wheezing | 384.64 | 19.55 | 238 | 13997 | 74788 | 56203044 |
Obstructive airways disorder | 364.34 | 19.55 | 144 | 14091 | 17138 | 56260694 |
Full blood count abnormal | 233.54 | 19.55 | 120 | 14115 | 26342 | 56251490 |
Nasal congestion | 206.21 | 19.55 | 145 | 14090 | 56225 | 56221607 |
Therapeutic product effect incomplete | 158.66 | 19.55 | 163 | 14072 | 105868 | 56171964 |
Dyspnoea | 143.82 | 19.55 | 399 | 13836 | 592178 | 55685654 |
Sleep disorder due to a general medical condition | 125.21 | 19.55 | 56 | 14179 | 9034 | 56268798 |
Gastrooesophageal reflux disease | 124.49 | 19.55 | 128 | 14107 | 83129 | 56194703 |
Bronchial haemorrhage | 120.35 | 19.55 | 28 | 14207 | 529 | 56277303 |
Bronchial neoplasm | 119.75 | 19.55 | 27 | 14208 | 441 | 56277391 |
Blepharospasm | 110.70 | 19.55 | 39 | 14196 | 3359 | 56274473 |
Cough | 109.90 | 19.55 | 218 | 14017 | 259743 | 56018089 |
Throat clearing | 109.71 | 19.55 | 32 | 14203 | 1498 | 56276334 |
Nasal turbinate hypertrophy | 108.45 | 19.55 | 27 | 14208 | 686 | 56277146 |
Chronic sinusitis | 107.11 | 19.55 | 49 | 14186 | 8329 | 56269503 |
Chest discomfort | 104.79 | 19.55 | 127 | 14108 | 98730 | 56179102 |
Bronchiectasis | 104.13 | 19.55 | 53 | 14182 | 11381 | 56266451 |
Blood immunoglobulin E increased | 103.65 | 19.55 | 36 | 14199 | 2973 | 56274859 |
Endometrial ablation | 102.06 | 19.55 | 27 | 14208 | 878 | 56276954 |
Productive cough | 101.79 | 19.55 | 96 | 14139 | 56136 | 56221696 |
Bronchial disorder | 99.42 | 19.55 | 28 | 14207 | 1155 | 56276677 |
Malignant mediastinal neoplasm | 87.91 | 19.55 | 24 | 14211 | 881 | 56276951 |
Rhonchi | 83.72 | 19.55 | 29 | 14206 | 2375 | 56275457 |
Taste disorder | 82.60 | 19.55 | 43 | 14192 | 9672 | 56268160 |
Nasal polyps | 82.25 | 19.55 | 31 | 14204 | 3234 | 56274598 |
Dust allergy | 82.19 | 19.55 | 21 | 14214 | 594 | 56277238 |
Sputum discoloured | 79.83 | 19.55 | 48 | 14187 | 14244 | 56263588 |
Hyper IgE syndrome | 78.96 | 19.55 | 19 | 14216 | 417 | 56277415 |
Respiratory tract inflammation | 73.54 | 19.55 | 19 | 14216 | 562 | 56277270 |
Total lung capacity increased | 72.94 | 19.55 | 21 | 14214 | 938 | 56276894 |
Dyspnoea exertional | 72.65 | 19.55 | 79 | 14156 | 54610 | 56223222 |
Rhinorrhoea | 71.63 | 19.55 | 80 | 14155 | 56957 | 56220875 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 69.48 | 19.55 | 19 | 14216 | 702 | 56277130 |
Rhinitis | 68.82 | 19.55 | 37 | 14198 | 8879 | 56268953 |
Secretion discharge | 68.34 | 19.55 | 39 | 14196 | 10507 | 56267325 |
Restrictive pulmonary disease | 67.35 | 19.55 | 22 | 14213 | 1504 | 56276328 |
Breath sounds abnormal | 65.69 | 19.55 | 36 | 14199 | 8971 | 56268861 |
Affective disorder | 63.03 | 19.55 | 30 | 14205 | 5573 | 56272259 |
Chronic obstructive pulmonary disease | 61.16 | 19.55 | 74 | 14161 | 57341 | 56220491 |
Nasal obstruction | 59.14 | 19.55 | 19 | 14216 | 1232 | 56276600 |
Blood test abnormal | 58.92 | 19.55 | 38 | 14197 | 12746 | 56265086 |
Granuloma | 57.54 | 19.55 | 28 | 14207 | 5459 | 56272373 |
Eczema | 55.81 | 19.55 | 49 | 14186 | 26104 | 56251728 |
Sleep apnoea syndrome | 53.96 | 19.55 | 48 | 14187 | 26013 | 56251819 |
Paraesthesia oral | 52.35 | 19.55 | 37 | 14198 | 14412 | 56263420 |
Weight decreased | 50.12 | 19.55 | 154 | 14081 | 240560 | 56037272 |
Haemoptysis | 49.28 | 19.55 | 46 | 14189 | 26514 | 56251318 |
Procedural pain | 48.42 | 19.55 | 37 | 14198 | 16234 | 56261598 |
Polycystic ovaries | 47.50 | 19.55 | 21 | 14214 | 3293 | 56274539 |
Respiratory disorder | 46.74 | 19.55 | 50 | 14185 | 33907 | 56243925 |
Sarcoidosis | 45.85 | 19.55 | 24 | 14211 | 5456 | 56272376 |
Lung hyperinflation | 43.84 | 19.55 | 15 | 14220 | 1183 | 56276649 |
Death | 43.54 | 19.55 | 16 | 14219 | 341410 | 55936422 |
Toxicity to various agents | 42.27 | 19.55 | 4 | 14231 | 224560 | 56053272 |
Rhinitis allergic | 41.06 | 19.55 | 26 | 14209 | 8448 | 56269384 |
Epilepsy | 39.85 | 19.55 | 40 | 14195 | 25191 | 56252641 |
Lactose intolerance | 38.51 | 19.55 | 17 | 14218 | 2655 | 56275177 |
Forced expiratory volume decreased | 37.82 | 19.55 | 20 | 14215 | 4640 | 56273192 |
Eye pruritus | 37.29 | 19.55 | 30 | 14205 | 14176 | 56263656 |
Dyslipidaemia | 37.19 | 19.55 | 22 | 14213 | 6331 | 56271501 |
Sinusitis | 37.06 | 19.55 | 122 | 14113 | 197459 | 56080373 |
Rheumatoid arthritis | 36.76 | 19.55 | 26 | 14209 | 382578 | 55895254 |
Crystal arthropathy | 35.38 | 19.55 | 9 | 14226 | 250 | 56277582 |
Alopecia | 35.35 | 19.55 | 15 | 14220 | 293443 | 55984389 |
Drug ineffective | 35.15 | 19.55 | 370 | 13865 | 918619 | 55359213 |
Systemic lupus erythematosus | 34.44 | 19.55 | 3 | 14232 | 180075 | 56097757 |
Migraine | 34.39 | 19.55 | 71 | 14164 | 86726 | 56191106 |
Ear pruritus | 33.92 | 19.55 | 16 | 14219 | 2912 | 56274920 |
Herpes zoster | 32.35 | 19.55 | 64 | 14171 | 75825 | 56202007 |
Arthropathy | 31.92 | 19.55 | 6 | 14229 | 200269 | 56077563 |
Ligament pain | 31.84 | 19.55 | 8 | 14227 | 211 | 56277621 |
Rales | 30.83 | 19.55 | 24 | 14211 | 10816 | 56267016 |
Dyspepsia | 30.42 | 19.55 | 66 | 14169 | 83405 | 56194427 |
Sneezing | 28.96 | 19.55 | 27 | 14208 | 15533 | 56262299 |
Asthmatic crisis | 28.32 | 19.55 | 12 | 14223 | 1698 | 56276134 |
Ankle fracture | 27.74 | 19.55 | 27 | 14208 | 16376 | 56261456 |
Bronchitis | 27.29 | 19.55 | 76 | 14159 | 112235 | 56165597 |
Seasonal allergy | 26.79 | 19.55 | 27 | 14208 | 17081 | 56260751 |
Paraesthesia | 26.64 | 19.55 | 83 | 14152 | 130431 | 56147401 |
Glossodynia | 25.53 | 19.55 | 4 | 14231 | 152454 | 56125378 |
Blood pressure diastolic abnormal | 25.28 | 19.55 | 22 | 14213 | 11576 | 56266256 |
Eosinophilia | 24.91 | 19.55 | 28 | 14207 | 20049 | 56257783 |
Eosinophil count increased | 24.55 | 19.55 | 20 | 14215 | 9617 | 56268215 |
Blood pressure systolic increased | 23.18 | 19.55 | 39 | 14196 | 40797 | 56237035 |
Sinus pain | 23.14 | 19.55 | 12 | 14223 | 2676 | 56275156 |
Pertussis | 23.09 | 19.55 | 8 | 14227 | 655 | 56277177 |
Loss of personal independence in daily activities | 22.73 | 19.55 | 58 | 14177 | 81311 | 56196521 |
Stent placement | 22.65 | 19.55 | 13 | 14222 | 3538 | 56274294 |
Sinus tachycardia | 22.38 | 19.55 | 28 | 14207 | 22416 | 56255416 |
Swelling face | 22.35 | 19.55 | 46 | 14189 | 56023 | 56221809 |
Chondrocalcinosis pyrophosphate | 21.84 | 19.55 | 9 | 14226 | 1188 | 56276644 |
Sensitivity to weather change | 21.74 | 19.55 | 16 | 14219 | 6633 | 56271199 |
Contraindicated product administered | 21.66 | 19.55 | 10 | 14225 | 186276 | 56091556 |
Restless legs syndrome | 21.65 | 19.55 | 24 | 14211 | 16923 | 56260909 |
Joint swelling | 21.48 | 19.55 | 25 | 14210 | 289775 | 55988057 |
Angioedema | 21.45 | 19.55 | 38 | 14197 | 41415 | 56236417 |
Respiratory tract infection | 21.21 | 19.55 | 35 | 14200 | 36036 | 56241796 |
Subclavian vein thrombosis | 21.19 | 19.55 | 10 | 14225 | 1822 | 56276010 |
Abscess | 20.38 | 19.55 | 22 | 14213 | 15059 | 56262773 |
Hepatic enzyme increased | 20.23 | 19.55 | 9 | 14226 | 171375 | 56106457 |
Blood pressure systolic abnormal | 20.21 | 19.55 | 18 | 14217 | 9759 | 56268073 |
Blood pressure diastolic increased | 20.21 | 19.55 | 17 | 14218 | 8544 | 56269288 |
Radioallergosorbent test positive | 20.14 | 19.55 | 4 | 14231 | 34 | 56277798 |
Allergy to animal | 20.07 | 19.55 | 8 | 14227 | 969 | 56276863 |
Pulmonary function test decreased | 19.89 | 19.55 | 12 | 14223 | 3579 | 56274253 |
Thrombocytopenia | 19.83 | 19.55 | 5 | 14230 | 136219 | 56141613 |
Cardiac murmur | 19.72 | 19.55 | 19 | 14216 | 11382 | 56266450 |
Stress | 19.68 | 19.55 | 45 | 14190 | 58865 | 56218967 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 367.08 | 19.67 | 180 | 6646 | 42431 | 31648087 |
Wheezing | 201.08 | 19.67 | 114 | 6712 | 35872 | 31654646 |
Appendicolith | 103.98 | 19.67 | 41 | 6785 | 5690 | 31684828 |
Nasal polyps | 85.04 | 19.67 | 27 | 6799 | 1986 | 31688532 |
Therapeutic product effect incomplete | 84.21 | 19.67 | 72 | 6754 | 43624 | 31646894 |
Appendicitis | 76.78 | 19.67 | 41 | 6785 | 11424 | 31679094 |
Sleep disorder due to a general medical condition | 74.60 | 19.67 | 29 | 6797 | 3873 | 31686645 |
Nasal congestion | 71.35 | 19.67 | 48 | 6778 | 20333 | 31670185 |
Obstructive airways disorder | 67.58 | 19.67 | 39 | 6787 | 12625 | 31677893 |
Foetal malformation | 66.09 | 19.67 | 13 | 6813 | 125 | 31690393 |
Stress | 58.28 | 19.67 | 46 | 6780 | 24895 | 31665623 |
Rhinitis | 57.59 | 19.67 | 26 | 6800 | 5038 | 31685480 |
Seasonal allergy | 55.15 | 19.67 | 26 | 6800 | 5562 | 31684956 |
Ocular discomfort | 54.53 | 19.67 | 19 | 6807 | 1864 | 31688654 |
Trisomy 18 | 53.15 | 19.67 | 13 | 6813 | 362 | 31690156 |
Cough | 53.08 | 19.67 | 100 | 6726 | 134714 | 31555804 |
Cardiogenic shock | 51.65 | 19.67 | 41 | 6785 | 22367 | 31668151 |
Full blood count abnormal | 51.30 | 19.67 | 36 | 6790 | 16311 | 31674207 |
Sputum discoloured | 50.39 | 19.67 | 26 | 6800 | 6750 | 31683768 |
Blood phosphorus increased | 47.78 | 19.67 | 22 | 6804 | 4460 | 31686058 |
Eye pruritus | 45.30 | 19.67 | 22 | 6804 | 5023 | 31685495 |
Middle insomnia | 41.35 | 19.67 | 22 | 6804 | 6077 | 31684441 |
Glaucoma | 40.42 | 19.67 | 22 | 6804 | 6358 | 31684160 |
Ventricular fibrillation | 40.28 | 19.67 | 33 | 6793 | 18815 | 31671703 |
Nasal oedema | 39.58 | 19.67 | 10 | 6816 | 319 | 31690199 |
Dyspnoea | 39.55 | 19.67 | 162 | 6664 | 343317 | 31347201 |
Chest discomfort | 38.16 | 19.67 | 50 | 6776 | 49319 | 31641199 |
Dermatitis allergic | 36.08 | 19.67 | 20 | 6806 | 5989 | 31684529 |
Eczema | 35.07 | 19.67 | 28 | 6798 | 15389 | 31675129 |
Anosmia | 34.47 | 19.67 | 14 | 6812 | 2094 | 31688424 |
Loss of personal independence in daily activities | 34.11 | 19.67 | 36 | 6790 | 28252 | 31662266 |
Lung diffusion disorder | 33.38 | 19.67 | 7 | 6819 | 95 | 31690423 |
Forced expiratory volume decreased | 32.95 | 19.67 | 15 | 6811 | 2962 | 31687556 |
Chronic obstructive pulmonary disease | 32.22 | 19.67 | 44 | 6782 | 45122 | 31645396 |
SARS-CoV-2 sepsis | 31.68 | 19.67 | 7 | 6819 | 123 | 31690395 |
Ocular hyperaemia | 31.29 | 19.67 | 22 | 6804 | 9987 | 31680531 |
Abdominal distension | 31.18 | 19.67 | 46 | 6780 | 50638 | 31639880 |
Central obesity | 30.93 | 19.67 | 9 | 6817 | 492 | 31690026 |
Ascites | 30.85 | 19.67 | 41 | 6785 | 40972 | 31649546 |
Productive cough | 30.73 | 19.67 | 37 | 6789 | 33503 | 31657015 |
Pharyngeal paraesthesia | 29.97 | 19.67 | 9 | 6817 | 549 | 31689969 |
Victim of child abuse | 29.51 | 19.67 | 10 | 6816 | 902 | 31689616 |
Fungal disease carrier | 26.81 | 19.67 | 7 | 6819 | 255 | 31690263 |
Nasal disorder | 26.59 | 19.67 | 11 | 6815 | 1724 | 31688794 |
Inguinal hernia repair | 26.44 | 19.67 | 7 | 6819 | 269 | 31690249 |
Polyp | 25.30 | 19.67 | 13 | 6813 | 3343 | 31687175 |
Gastroenteritis eosinophilic | 24.89 | 19.67 | 6 | 6820 | 157 | 31690361 |
Nasal septum deviation | 24.81 | 19.67 | 9 | 6817 | 992 | 31689526 |
Conjunctivitis | 24.76 | 19.67 | 18 | 6808 | 8605 | 31681913 |
Hyponatraemia | 24.45 | 19.67 | 51 | 6775 | 73748 | 31616770 |
Laryngeal discomfort | 23.64 | 19.67 | 6 | 6820 | 195 | 31690323 |
Alpha 2 globulin decreased | 22.61 | 19.67 | 4 | 6822 | 20 | 31690498 |
Otosalpingitis | 22.61 | 19.67 | 4 | 6822 | 20 | 31690498 |
Free androgen index decreased | 22.45 | 19.67 | 4 | 6822 | 21 | 31690497 |
Sex hormone binding globulin decreased | 22.45 | 19.67 | 4 | 6822 | 21 | 31690497 |
Androgen insensitivity syndrome | 22.29 | 19.67 | 4 | 6822 | 22 | 31690496 |
Viral acanthoma | 22.29 | 19.67 | 4 | 6822 | 22 | 31690496 |
Rhinorrhoea | 22.09 | 19.67 | 26 | 6800 | 22986 | 31667532 |
Testicular microlithiasis | 22.00 | 19.67 | 4 | 6822 | 24 | 31690494 |
Toxicity to various agents | 21.92 | 19.67 | 6 | 6820 | 181481 | 31509037 |
Dehydroepiandrosterone decreased | 21.86 | 19.67 | 4 | 6822 | 25 | 31690493 |
Urine calcium/creatinine ratio increased | 21.86 | 19.67 | 4 | 6822 | 25 | 31690493 |
Eosinophilic pneumonia chronic | 21.82 | 19.67 | 6 | 6820 | 267 | 31690251 |
Faecal calprotectin | 21.59 | 19.67 | 4 | 6822 | 27 | 31690491 |
Bronchial obstruction | 21.51 | 19.67 | 9 | 6817 | 1451 | 31689067 |
Rhinitis allergic | 21.35 | 19.67 | 11 | 6815 | 2843 | 31687675 |
Cortisol decreased | 21.26 | 19.67 | 8 | 6818 | 977 | 31689541 |
Sinusitis | 20.70 | 19.67 | 32 | 6794 | 36664 | 31653854 |
Blue toe syndrome | 20.41 | 19.67 | 5 | 6821 | 140 | 31690378 |
Blood test abnormal | 20.37 | 19.67 | 14 | 6812 | 6127 | 31684391 |
Oropharyngeal candidiasis | 20.18 | 19.67 | 7 | 6819 | 677 | 31689841 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 843.94 | 17.28 | 476 | 18415 | 120317 | 70789236 |
Wheezing | 519.62 | 17.28 | 319 | 18572 | 93851 | 70815702 |
Obstructive airways disorder | 381.04 | 17.28 | 170 | 18721 | 25943 | 70883610 |
Full blood count abnormal | 278.36 | 17.28 | 149 | 18742 | 33729 | 70875824 |
Nasal congestion | 264.87 | 17.28 | 183 | 18708 | 65489 | 70844064 |
Therapeutic product effect incomplete | 208.92 | 17.28 | 205 | 18686 | 119677 | 70789876 |
Sleep disorder due to a general medical condition | 161.71 | 17.28 | 71 | 18820 | 10405 | 70899148 |
Dyspnoea | 154.82 | 17.28 | 502 | 18389 | 769558 | 70139995 |
Nasal polyps | 148.91 | 17.28 | 53 | 18838 | 4463 | 70905090 |
Cough | 148.05 | 17.28 | 290 | 18601 | 325087 | 70584466 |
Rhinitis | 124.40 | 17.28 | 61 | 18830 | 11486 | 70898067 |
Chest discomfort | 122.37 | 17.28 | 158 | 18733 | 124223 | 70785330 |
Productive cough | 119.94 | 17.28 | 125 | 18766 | 78212 | 70831341 |
Gastrooesophageal reflux disease | 119.89 | 17.28 | 134 | 18757 | 90705 | 70818848 |
Bronchial neoplasm | 117.90 | 17.28 | 27 | 18864 | 449 | 70909104 |
Sputum discoloured | 116.95 | 17.28 | 69 | 18822 | 18782 | 70890771 |
Nasal turbinate hypertrophy | 116.32 | 17.28 | 28 | 18863 | 583 | 70908970 |
Throat clearing | 108.80 | 17.28 | 33 | 18858 | 1678 | 70907875 |
Endometrial ablation | 102.66 | 17.28 | 27 | 18864 | 813 | 70908740 |
Chronic sinusitis | 101.18 | 17.28 | 48 | 18843 | 8403 | 70901150 |
Bronchiectasis | 100.06 | 17.28 | 59 | 18832 | 16038 | 70893515 |
Blepharospasm | 96.78 | 17.28 | 37 | 18854 | 3808 | 70905745 |
Bronchial haemorrhage | 96.08 | 17.28 | 28 | 18863 | 1239 | 70908314 |
Rhonchi | 94.98 | 17.28 | 36 | 18855 | 3619 | 70905934 |
Appendicolith | 92.55 | 17.28 | 40 | 18851 | 5640 | 70903913 |
Blood immunoglobulin E increased | 89.25 | 17.28 | 37 | 18854 | 4707 | 70904846 |
Rhinorrhoea | 87.69 | 17.28 | 98 | 18793 | 66273 | 70843280 |
Malignant mediastinal neoplasm | 82.86 | 17.28 | 23 | 18868 | 852 | 70908701 |
Eczema | 80.66 | 17.28 | 69 | 18822 | 33712 | 70875841 |
Blood test abnormal | 79.13 | 17.28 | 49 | 18842 | 14541 | 70895012 |
Bronchial disorder | 79.02 | 17.28 | 28 | 18863 | 2326 | 70907227 |
Chronic obstructive pulmonary disease | 76.88 | 17.28 | 99 | 18792 | 77542 | 70832011 |
Restrictive pulmonary disease | 75.78 | 17.28 | 27 | 18864 | 2279 | 70907274 |
Hyper IgE syndrome | 75.51 | 17.28 | 19 | 18872 | 478 | 70909075 |
Taste disorder | 74.11 | 17.28 | 43 | 18848 | 11342 | 70898211 |
Toxicity to various agents | 71.19 | 17.28 | 9 | 18882 | 382163 | 70527390 |
Stress | 70.98 | 17.28 | 89 | 18802 | 67877 | 70841676 |
Total lung capacity increased | 67.77 | 17.28 | 20 | 18871 | 925 | 70908628 |
Dust allergy | 67.50 | 17.28 | 21 | 18870 | 1163 | 70908390 |
Eye pruritus | 66.55 | 17.28 | 44 | 18847 | 14603 | 70894950 |
Respiratory tract inflammation | 65.74 | 17.28 | 19 | 18872 | 816 | 70908737 |
Forced expiratory volume decreased | 65.20 | 17.28 | 34 | 18857 | 7280 | 70902273 |
Affective disorder | 64.49 | 17.28 | 34 | 18857 | 7445 | 70902108 |
Breath sounds abnormal | 63.18 | 17.28 | 41 | 18850 | 13190 | 70896363 |
Secretion discharge | 61.56 | 17.28 | 40 | 18851 | 12893 | 70896660 |
Macular degeneration | 61.46 | 17.28 | 33 | 18858 | 7495 | 70902058 |
Sleep apnoea syndrome | 56.96 | 17.28 | 56 | 18835 | 32657 | 70876896 |
Seasonal allergy | 55.27 | 17.28 | 38 | 18853 | 13446 | 70896107 |
Paraesthesia oral | 55.20 | 17.28 | 40 | 18851 | 15377 | 70894176 |
Sinusitis | 55.13 | 17.28 | 132 | 18759 | 169063 | 70740490 |
Respiratory disorder | 53.78 | 17.28 | 59 | 18832 | 39064 | 70870489 |
Nasal obstruction | 53.62 | 17.28 | 19 | 18872 | 1578 | 70907975 |
Dyspnoea exertional | 52.50 | 17.28 | 83 | 18808 | 78347 | 70831206 |
Appendicitis | 52.27 | 17.28 | 40 | 18851 | 16693 | 70892860 |
Granuloma | 49.91 | 17.28 | 29 | 18862 | 7666 | 70901887 |
Rhinitis allergic | 49.85 | 17.28 | 31 | 18860 | 9264 | 70900289 |
Polycystic ovaries | 49.34 | 17.28 | 21 | 18870 | 2851 | 70906702 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 46.48 | 17.28 | 17 | 18874 | 1547 | 70908006 |
Loss of personal independence in daily activities | 45.05 | 17.28 | 81 | 18810 | 84829 | 70824724 |
Middle insomnia | 44.79 | 17.28 | 34 | 18857 | 14019 | 70895534 |
Weight decreased | 44.53 | 17.28 | 182 | 18709 | 310306 | 70599247 |
Migraine | 43.66 | 17.28 | 73 | 18818 | 72165 | 70837388 |
Anosmia | 41.53 | 17.28 | 22 | 18869 | 4861 | 70904692 |
Lung hyperinflation | 41.31 | 17.28 | 16 | 18875 | 1705 | 70907848 |
Lactose intolerance | 41.16 | 17.28 | 17 | 18874 | 2141 | 70907412 |
Procedural pain | 39.38 | 17.28 | 35 | 18856 | 17974 | 70891579 |
Death | 37.08 | 17.28 | 49 | 18842 | 510012 | 70399541 |
Anaemia | 36.84 | 17.28 | 32 | 18859 | 403391 | 70506162 |
Bronchitis | 36.59 | 17.28 | 90 | 18801 | 117153 | 70792400 |
Acute kidney injury | 35.11 | 17.28 | 45 | 18846 | 474579 | 70434974 |
Blood phosphorus increased | 34.85 | 17.28 | 22 | 18869 | 6748 | 70902805 |
Polyp | 33.69 | 17.28 | 22 | 18869 | 7148 | 70902405 |
Blood pressure diastolic increased | 33.07 | 17.28 | 27 | 18864 | 12364 | 70897189 |
Sarcoidosis | 32.78 | 17.28 | 21 | 18870 | 6606 | 70902947 |
Ear pruritus | 32.41 | 17.28 | 16 | 18875 | 3054 | 70906499 |
Thrombocytopenia | 31.73 | 17.28 | 12 | 18879 | 239098 | 70670455 |
Herpes zoster | 31.59 | 17.28 | 70 | 18821 | 85165 | 70824388 |
Epilepsy | 31.59 | 17.28 | 45 | 18846 | 38739 | 70870814 |
Cardiac murmur | 31.36 | 17.28 | 26 | 18865 | 12160 | 70897393 |
Haemoptysis | 31.09 | 17.28 | 52 | 18839 | 51400 | 70858153 |
Lower respiratory tract infection | 30.86 | 17.28 | 82 | 18809 | 111831 | 70797722 |
Nasal oedema | 30.83 | 17.28 | 12 | 18879 | 1295 | 70908258 |
Swelling face | 30.65 | 17.28 | 58 | 18833 | 63106 | 70846447 |
Ligament pain | 30.16 | 17.28 | 8 | 18883 | 249 | 70909304 |
SARS-CoV-2 sepsis | 30.04 | 17.28 | 7 | 18884 | 126 | 70909427 |
Ankle fracture | 29.99 | 17.28 | 28 | 18863 | 15316 | 70894237 |
Dyslipidaemia | 29.55 | 17.28 | 23 | 18868 | 9837 | 70899716 |
Eosinophilic pneumonia chronic | 29.31 | 17.28 | 9 | 18882 | 477 | 70909076 |
Lung diffusion disorder | 29.30 | 17.28 | 7 | 18884 | 141 | 70909412 |
Dehydration | 28.93 | 17.28 | 12 | 18879 | 226130 | 70683423 |
Cardiogenic shock | 27.92 | 17.28 | 41 | 18850 | 36266 | 70873287 |
Sneezing | 27.63 | 17.28 | 28 | 18863 | 16923 | 70892630 |
Eosinophilia | 27.42 | 17.28 | 43 | 18848 | 40276 | 70869277 |
Dyspepsia | 27.38 | 17.28 | 68 | 18823 | 89009 | 70820544 |
Victim of child abuse | 27.15 | 17.28 | 10 | 18881 | 928 | 70908625 |
Ocular discomfort | 27.08 | 17.28 | 16 | 18875 | 4361 | 70905192 |
Cardiac arrest | 26.90 | 17.28 | 5 | 18886 | 159829 | 70749724 |
Asthmatic crisis | 26.60 | 17.28 | 12 | 18879 | 1872 | 70907681 |
Haemoglobin decreased | 26.06 | 17.28 | 11 | 18880 | 205148 | 70704405 |
Paraesthesia | 25.50 | 17.28 | 91 | 18800 | 145446 | 70764107 |
Treatment failure | 25.38 | 17.28 | 4 | 18887 | 144138 | 70765415 |
Inguinal hernia repair | 25.10 | 17.28 | 7 | 18884 | 264 | 70909289 |
Fungal disease carrier | 24.16 | 17.28 | 7 | 18884 | 303 | 70909250 |
Blood pressure diastolic abnormal | 24.16 | 17.28 | 25 | 18866 | 15479 | 70894074 |
Synovitis | 24.13 | 17.28 | 3 | 18888 | 129225 | 70780328 |
Neutropenia | 23.93 | 17.28 | 20 | 18871 | 257136 | 70652417 |
Atopy | 23.86 | 17.28 | 7 | 18884 | 317 | 70909236 |
Sensitivity to weather change | 23.78 | 17.28 | 18 | 18873 | 7387 | 70902166 |
Platelet count decreased | 23.54 | 17.28 | 9 | 18882 | 178213 | 70731340 |
Eosinophilic granulomatosis with polyangiitis | 23.23 | 17.28 | 13 | 18878 | 3200 | 70906353 |
Throat irritation | 23.11 | 17.28 | 37 | 18854 | 35267 | 70874286 |
Oropharyngeal pain | 23.02 | 17.28 | 67 | 18824 | 96243 | 70813310 |
Ventricular fibrillation | 22.88 | 17.28 | 32 | 18859 | 27079 | 70882474 |
Eosinophil count increased | 22.74 | 17.28 | 24 | 18867 | 15198 | 70894355 |
Blood pressure systolic increased | 22.32 | 17.28 | 48 | 18843 | 57211 | 70852342 |
Rheumatoid arthritis | 22.24 | 17.28 | 27 | 18864 | 291778 | 70617775 |
Ovarian cyst | 22.08 | 17.28 | 21 | 18870 | 11751 | 70897802 |
Overdose | 21.72 | 17.28 | 9 | 18882 | 169736 | 70739817 |
Gastrointestinal haemorrhage | 21.67 | 17.28 | 5 | 18886 | 137403 | 70772150 |
Respiratory failure | 21.50 | 17.28 | 9 | 18882 | 168726 | 70740827 |
Cardiac failure congestive | 21.22 | 17.28 | 5 | 18886 | 135452 | 70774101 |
Crepitations | 21.20 | 17.28 | 18 | 18873 | 8696 | 70900857 |
Gastroenteritis eosinophilic | 21.17 | 17.28 | 6 | 18885 | 240 | 70909313 |
Pertussis | 20.67 | 17.28 | 8 | 18883 | 851 | 70908702 |
Respiratory tract infection | 20.65 | 17.28 | 39 | 18852 | 42359 | 70867194 |
Rales | 20.41 | 17.28 | 24 | 18867 | 17111 | 70892442 |
Cortisol decreased | 20.31 | 17.28 | 10 | 18881 | 1897 | 70907656 |
White blood cell count decreased | 20.24 | 17.28 | 10 | 18881 | 170131 | 70739422 |
Nasal disorder | 20.20 | 17.28 | 12 | 18879 | 3302 | 70906251 |
Febrile neutropenia | 20.13 | 17.28 | 15 | 18876 | 204303 | 70705250 |
Sinus disorder | 20.05 | 17.28 | 25 | 18866 | 18934 | 70890619 |
Radioallergosorbent test positive | 20.04 | 17.28 | 4 | 18887 | 33 | 70909520 |
Joint swelling | 19.75 | 17.28 | 23 | 18868 | 253188 | 70656365 |
Asthenia | 19.47 | 17.28 | 60 | 18831 | 457606 | 70451947 |
Drug interaction | 19.23 | 17.28 | 46 | 18845 | 381395 | 70528158 |
Ocular hyperaemia | 19.20 | 17.28 | 28 | 18863 | 24611 | 70884942 |
Autism spectrum disorder | 18.97 | 17.28 | 8 | 18883 | 1062 | 70908491 |
Central obesity | 18.86 | 17.28 | 9 | 18882 | 1594 | 70907959 |
Pharyngeal paraesthesia | 18.82 | 17.28 | 10 | 18881 | 2222 | 70907331 |
Diarrhoea | 18.77 | 17.28 | 127 | 18764 | 783214 | 70126339 |
Sinus pain | 18.42 | 17.28 | 11 | 18880 | 3058 | 70906495 |
Influenza | 18.15 | 17.28 | 69 | 18822 | 113631 | 70795922 |
Malignant neoplasm progression | 18.10 | 17.28 | 5 | 18886 | 121734 | 70787819 |
Eosinophilic bronchitis | 18.09 | 17.28 | 6 | 18885 | 408 | 70909145 |
Hypotension | 17.92 | 17.28 | 52 | 18839 | 404329 | 70505224 |
Septic shock | 17.87 | 17.28 | 4 | 18887 | 112254 | 70797299 |
Illness | 17.71 | 17.28 | 31 | 18860 | 31760 | 70877793 |
Lung neoplasm malignant | 17.68 | 17.28 | 27 | 18864 | 24715 | 70884838 |
Restless legs syndrome | 17.44 | 17.28 | 23 | 18868 | 18405 | 70891148 |
None
Source | Code | Description |
---|---|---|
ATC | D07AC17 | DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III) |
ATC | R01AD08 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R01AD12 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R01AD58 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R03AK06 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK10 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AL08 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03BA05 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids |
ATC | R03BA09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids |
FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
FDA EPC | N0000175576 | Corticosteroid |
CHEBI has role | CHEBI:49167 | anti-asthmatic drugs |
CHEBI has role | CHEBI:50857 | anti-allergic drugs |
MeSH PA | D018926 | Anti-Allergic Agents |
MeSH PA | D018927 | Anti-Asthmatic Agents |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D001993 | Bronchodilator Agents |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D019141 | Respiratory System Agents |
CHEBI has role | CHEBI:50266 | Prodrugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic obstructive lung disease | indication | 13645005 | DOID:3083 |
Allergic rhinitis | indication | 61582004 | |
Chronic bronchitis | indication | 63480004 | DOID:6132 |
Pulmonary emphysema | indication | 87433001 | |
Asthma | indication | 195967001 | DOID:2841 |
Chronic Non-Allergic Rhinitis | indication | ||
Mycosis | contraindication | 3218000 | DOID:1564 |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Epistaxis | contraindication | 12441001 | |
Measles | contraindication | 14189004 | DOID:8622 |
Disease caused by parasite | contraindication | 17322007 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Viral disease | contraindication | 34014006 | DOID:934 |
Hypercortisolism | contraindication | 47270006 | |
Perforation of nasal septum | contraindication | 80142000 | |
Bacterial infectious disease | contraindication | 87628006 | |
Operation on nose | contraindication | 88733004 | |
Bilateral cataracts | contraindication | 95722004 | |
Pulmonary tuberculosis | contraindication | 154283005 | DOID:2957 |
Ophthalmic herpes simplex | contraindication | 186542001 | |
Varicella-zoster virus infection | contraindication | 309465005 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Exposure to varicella | contraindication | 444453009 | |
Nasal Candidiasis | contraindication | ||
Nasal Trauma | contraindication | ||
Nasal Septal Ulcers | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.49 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8309572 | April 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8309572 | April 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 11090294 | Nov. 29, 2030 | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | Sept. 9, 2023 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | Sept. 9, 2023 | NEW STRENGTH |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | IC50 | 10.12 | CHEMBL | CHEMBL | |||
Mineralocorticoid receptor | Nuclear hormone receptor | IC50 | 6.83 | CHEMBL | |||||
Progesterone receptor | Nuclear hormone receptor | IC50 | 7.68 | CHEMBL | |||||
Androgen receptor | Transcription factor | IC50 | 5.73 | CHEMBL | |||||
Glucocorticoid receptor | Transcription factor | IC50 | 8.30 | CHEMBL |
ID | Source |
---|---|
D06315 | KEGG_DRUG |
4026165 | VUID |
N0000179800 | NUI |
4020529 | VANDF |
4026165 | VANDF |
CHEBI:74899 | CHEBI |
CHEBI:5134 | CHEBI |
GW6 | PDB_CHEM_ID |
CHEMBL1676 | ChEMBL_ID |
C523187 | MESH_SUPPLEMENTAL_RECORD_UI |
10892 | IUPHAR_LIGAND_ID |
6699 | IUPHAR_LIGAND_ID |
8521 | INN_ID |
DB08906 | DRUGBANK_ID |
JS86977WNV | UNII |
DB13867 | DRUGBANK_ID |
41126 | RXNORM |
109674 | MMSL |
23848 | MMSL |
51966 | MMSL |
d01296 | MMSL |
004952 | NDDF |
012173 | NDDF |
108632003 | SNOMEDCT_US |
397192001 | SNOMEDCT_US |
426409006 | SNOMEDCT_US |
C1948374 | UMLSCUI |
C0082607 | UMLSCUI |
CHEMBL1201396 | ChEMBL_ID |
9854489 | PUBCHEM_CID |
5636 | INN_ID |
90566-53-3 | SECONDARY_CAS_RN |
D000068298 | MESH_DESCRIPTOR_UI |
5311101 | PUBCHEM_CID |
CUT2W21N7U | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 0135-0615 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 16 sections |
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 0135-0616 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 16 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0859 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0859 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0874 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0874 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0876 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0876 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0882 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0882 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0887 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0887 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0888 | POWDER | 50 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0888 | POWDER | 50 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0893 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0893 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 50090-5967 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 17 sections |
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 50090-6075 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 17 sections |
Veramyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6168 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 27 sections |
Fluticasone Furoate and Vilanterol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66993-135 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 26 sections |
Fluticasone Furoate and Vilanterol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66993-136 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-2028 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-2028 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |